Carcinoma, Transitional Cell: all 725 studies
Page 6 of 8. Open to participants first (201), then studies with results posted, then the rest; newest registration first within each.
- Study With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer Diseases With Positive PSCA MarkerTerminatedNCT03927573Phase 1
- KHK2455 (IDO Inhibitor) Plus Avelumab in Adult Subjects With Advanced Bladder CancerTerminatedNCT03915405Phase 1
- A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk TumorsCompletedNCT03914794Phase 2
- The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)Status unknownNCT03896958
- Improve Checkpoint-blockade Response in Advanced Urothelial CancerCompletedNCT03871036Phase 1/2
- Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial CarcinomaActive, not recruitingNCT03854474Phase 1/2
- Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological TumorsStatus unknownNCT03827837Phase 2
- Avelumab Program Rollover StudyActive, not recruitingNCT03815643Phase 3
- A Open-label, Single-arm, Multicenter, Phase II Study of RC48-ADC to Evaluate the Efficacy and Safety of Subjects With HER2 Overexpressing Locally Advanced or Metastatic Urothelial CancerCompletedNCT03809013Phase 2
- Prevalence of PD-L1 Expression in Patients With Advanced Urothelial CarcinomaCompletedNCT03788746
- A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical PracticeCompletedNCT03782207
- Paclitaxel and TAK-228 in Urothelial CarcinomaStatus unknownNCT03745911Phase 2
- Pemetrexed and Avelumab in Treating Patients With MTAP-Deficient Metastatic Urothelial CancerActive, not recruitingNCT03744793Phase 2
- Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid TumorsActive, not recruitingNCT03682289Phase 2
- Predictive Factorsfor Final Pathologic Ureteral SectionsCompletedNCT03677544
- A Clinical Study of PD-L1 Antibody ZKAB001（Drug Code） in Locally Advanced and Metastatic Urothelial CarcinomaStatus unknownNCT03676946Phase 1/2
- The Cxbladder Rule-out of Recurrent Urothelial CarcinomaStatus unknownNCT03673202
- A Study of a Personalized Neoantigen Cancer VaccineCompletedNCT03639714Phase 1/2
- The Efficacy of Neoadjuvant Atezolizumab Treatment in Patients With Advanced Urothelial Bladder CancerStatus unknownNCT03577132Not applicable
- A Combination of Avelumab and Taxane (AVETAX) for Urothelial CancerCompletedNCT03575013Phase 1
- NEoadjuvant Dose-dense MVAC In cOmbination With Durvalumab and Tremelimumab in Muscle-invasive Urothelial CarcinomaActive, not recruitingNCT03549715Phase 1/2
- Feasibility and Safety of Extraperitoneal Laparoscopic Extended Retroperitoneal Lymph Node Dissection at Time of Nephroureterectomy for Upper Tract Urothelial CarcinomaStatus unknownNCT03544437
- Radio-Immunotherapy Before Cystectomy in Locally Advanced Urothelial Carcinoma of the BladderStatus unknownNCT03529890Phase 2
- A Phase II Study of RC48-ADC in Subjects With HER2 Positive Metastatic or Unresectable Urothelial CancerCompletedNCT03507166Phase 2
- Pembrolizumab and Nab Paclitaxel in Patients With Metastatic Urothelial CarcinomaCompletedNCT03464734Phase 2
- Talimogene Laherparepvec in Treating Patients With Non-Muscle Invasive Bladder Transitional Cell CarcinomaWithdrawnNCT03430687Phase 1
- Radiation Therapy and Pembrolizumab in Treating Patients With Localized Urothelial Bladder CancerWithdrawnNCT03419130Phase 2
- A Study of TAR-200 in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Ineligible for or Refuse Cisplatin-based Chemotherapy and Who Are Unfit for Radical CystectomyCompletedNCT03404791Phase 1
- A Study to Investigate The Effectiveness Of Atezolizumab In Patients With Inoperable Locally-Advanced Or Metastatic Urothelial Carcinoma Of The Urinary Tract (Announce)TerminatedNCT03399643
- Avelumab Plus Carboplatin-gemcitabine in Urothelial CarcinomaCompletedNCT03390595Phase 2
- Autologous Cellular Immunotherapy in Patients With Metastatic Bladder Urothelial CarcinomaTerminatedNCT03389438Phase 2
- Neo-Adjuvant Bladder Urothelial Carcinoma COmbination-immunotherapyCompletedNCT03387761Phase 1
- A Study of the Safety of Atezolizumab in Patients With Advanced or Metastatic Urothelial Carcinoma in ArgentinaCompletedNCT03330886
- Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the BladderActive, not recruitingNCT03317158Phase 1/2
- Four Cycles Versus Six Cycles of Cisplatin-based Chemotherapy in Metastatic Urothelial CarcinomaStatus unknownNCT03296306Phase 3
- Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial CarcinomaActive, not recruitingNCT03291028
- A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial CancerTerminatedNCT03288545Phase 1/2
- A Superiority Trial to Compare Re-resection of High-grade T1 Bladder Urothelial Carcinoma to no Re-resection for Improving Progression Free SurvivalTerminatedNCT03266900Early Phase 1
- Biomarkers in Urothelial Cancer Patients Treated With PembrolizumabStatus unknownNCT03263039Phase 2
- Detecting Transitional Cell Carcinoma From HaematuriaCompletedNCT03256877
- Feasibility and Safety of IMP321 (Eftilagimod Alpha) for Advanced Stage Solid TumorsActive, not recruitingNCT03252938Phase 1
- Robot-Assisted Laparoscopic High-Intensity Focused Ultrasound and Radical Cystectomy for Thermal Ablation of Muscle Invasive Cells in Patients With Bladder TumorsWithdrawnNCT03238664Not applicable
- Lymph Node Dissection in High-risk UTUC(Upper Tract Urothelial Carcinoma)Status unknownNCT03230201Not applicable
- QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint InhibitorsActive, not recruitingNCT03228667Phase 2
- Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Transitional Cell CarcinomaStatus unknownNCT03219775Phase 2
- The Effectiveness and Safety of Intravesical Docetaxel Instillation for Prevent Bladder RecurrenceStatus unknownNCT03209206Phase 2
- Radium-223 and Atezolizumab in Patients With Urothelial Carcinoma With Bone Metastases Who Have Had Disease Progression After Platinum-Based ChemotherapyTerminatedNCT03208712Early Phase 1
- QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 TherapyWithdrawnNCT03197571Phase 1/2
- Pemetrexed Maintenance in Patients With Urothelial Carcinoma Who Completed First Line Platinum-based ChemotherapyStatus unknownNCT03193788Phase 3
- Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial CarcinomaActive, not recruitingNCT03179943Phase 2
- Trial of Intravesical Measles Virotherapy in Patients With Bladder Cancer Who Are Undergoing Radical CystectomyCompletedNCT03171493Phase 1
- Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid TumorsActive, not recruitingNCT03170960Phase 1
- Storz Professional Image Enhancement System Versus White Light Imaging Assisted TURBT for Treatment of NMIBCStatus unknownNCT03138824Not applicable
- Safety and Efficacy of Toripalimab for Patients With Locally Advanced or Metastatic Bladder Urothelial CarcinomaStatus unknownNCT03113266Phase 2
- A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder CancerCompletedNCT03093922Phase 2
- A Study Evaluating MM-310 in Patients With Solid TumorsStatus unknownNCT03076372Phase 1
- A Study of Enfortumab Vedotin in Japanese Subjects With Locally Advanced or Metastatic Urothelial CarcinomaCompletedNCT03070990Phase 1
- The Effectiveness and Safety of Intravesical Gemcitabine Instillation to Prevent Intravesical RecurrenceStatus unknownNCT03062059Phase 2
- Phase 2 Trial of Nab-paclitaxel Plus S-1 vs Gemcitabine Plus Cisplatin as 1-line Chemotherapy of Patients With Local Advanced and/or Metastatic Transitional Cell Carcinoma of Urothelial TractCompletedNCT03051373Phase 2
- Copper Cu-64 TP3805 PET/CT in Imaging Patients With Urothelial Cancer Undergoing Surgery or BiopsyCompletedNCT03039413Early Phase 1
- Single Versus Long-term Intravesical Instillation Chemotherapy for Recurrence After Nephroureterectomy for Upper Tract Urothelial CarcinomaStatus unknownNCT03030157Phase 2
- CLE Characteristics of Upper Urinary Tract Urothelial CarcinomaCompletedNCT03013920
- A Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder CancerActive, not recruitingNCT02989584Phase 1/2
- MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck CancersCompletedNCT02989064Phase 1
- SAbR Induced Innate Immunity in Urothelial Carcinoma, Melanoma, and Cervical CarcinomaCompletedNCT02986867Not applicable
- Cystoscopic Evaluation Predicting pT0 Urothelial Carcinoma of the BladderActive, not recruitingNCT02968732Not applicable
- Gemcitabine Hydrochloride, Cisplatin, and AGS-003-BLD in Treating Patients With Muscle-Invasive Bladder Cancer Undergoing SurgeryWithdrawnNCT02944357Not applicable
- Prophylactic Intravesical Chemotherapy to Prevent Bladder Recurrence After Nephroureterectomy for Primary Upper Tract Urothelial Carcinoma PatientsStatus unknownNCT02923557Phase 2
- A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder CancerCompletedNCT02897765Phase 1
- Neoadjuvant Chemotherapy Versus Surgery Alone in Patients With High-Grade UTUCCompletedNCT02876861Phase 2
- Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the BladderActive, not recruitingNCT02845323Phase 2
- Nivolumab and Ipilimumab in Treating Patients With Rare TumorsActive, not recruitingNCT02834013Phase 2
- I-MVAC +/- Panitumumab as First-line Treatment of Advanced Urothelial Carcinoma Without H-Ras Nor K-Ras MutationsCompletedNCT02818725Phase 3
- sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or Kidney CancerTerminatedNCT02767921Phase 1
- Urinary Biomarkers in the Detection of Urothelial Carcinoma of the BladderCompletedNCT02745301
- Prophylactic Intravesical Chemotherapy to Prevent Bladder Recurrence After Diagnostic Ureteroscopy for Primary Upper Tract Urothelial Carcinoma PatientsStatus unknownNCT02740426Phase 2
- Study of Intratumoral REOLYSIN® in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy in Muscle-invasive Transitional Cell Carcinoma of the BladderWithdrawnNCT02723838Phase 1
- Paclitaxel Albumin-Stabilized Nanoparticle Formulation After Cisplatin-Based Chemotherapy and Surgery in Treating Patients With High-Risk Bladder CancerWithdrawnNCT02718742Phase 2
- Multicohort Phase II Trial of sEphB4-HSA+Pembrolizumab in Solid TumorsActive, not recruitingNCT02717156Phase 2
- Compassionate Use of MitoGel in Upper Tract Urothelial CarcinomaNo longer availableNCT02701023
- The Cxbladder Monitoring StudyCompletedNCT02700659
- Quality of Life After Bladder-Preservation Chemotherapy and Radiation Therapy in Patients With Muscle-Invasive Bladder CancerWithdrawnNCT02688348Not applicable
- A Trial With Vinflunine in Patients With Metastatic Bladder Cancer and Impaired Renal FunctionCompletedNCT02665039Phase 2
- Preoperative MPDL3280A in Transitional Cell Carcinoma of the BladderCompletedNCT02662309Phase 2
- Utility of Bladder EpiCheck for Detection of Recurrent Urothelial CarcinomaCompletedNCT02647112Not applicable
- A Dose Escalation Study in Solid Tumors and a Dose Expansion Study of PRN1371 in Adult Patients With Metastatic Urothelial CarcinomaTerminatedNCT02608125Phase 1
- Lymphadenectomy in Urothelial CarcinomaSuspendedNCT02607709Not applicable
- An Expanded Access Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing ChemotherapyApproved for marketingNCT02589717
- Prophylactic Intravesical Chemotherapy to Prevent Bladder Tumors After Nephroureterectomy for Primary Upper Urinary Tract Urothelial CarcinomasStatus unknownNCT02547350Phase 2
- Study of Tipifarnib in Patients With Previously-Treated, Advanced, HRAS Mutant Urothelial CarcinomaStatus unknownNCT02535650Phase 2
- Ultrasound and Biomarker Tests in Predicting Cancer Aggressiveness in Tissue Samples of Patients With Bladder CancerTerminatedNCT02494635
- Study of the CD40 Agonistic Monoclonal Antibody APX005MCompletedNCT02482168Phase 1
- A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and NeckTerminatedNCT02479178Phase 2
- Intravesically Heated Thermo-chemotherapy With Mitomycin-C Prior to TURBTStatus unknownNCT02471547Not applicable
- Impact of Positron Emission Tomography (PET) Imaging in Muscle-invasive Urothelial Carcinoma of the Bladder StagingCompletedNCT02462239Not applicable
- Prophylactic Intravesical Chemotherapy After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: a Randomized Controlled Trial Between Single Postoperative Dose Versus Maintenance Therapy.CompletedNCT02438865Phase 2
- Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial CancerCompletedNCT02437370Phase 1
- Ixazomib Citrate With Gemcitabine Hydrochloride and Doxorubicin Hydrochloride in Treating Patients With Urothelial Cancer That is Metastatic or Cannot Be Removed by SurgeryActive, not recruitingNCT02420847Phase 1/2
- Diagnostic Accuracy of Optical Coherence Tomography in Upper Urinary Tract Urothelial CarcinomaCompletedNCT02326909Not applicable
- BIBF1120 in Patients With Advanced FGFR3 Mutated,Overexpressed,or Wild Type Urothelial CarcinomaStatus unknownNCT02278978Phase 2